Key messages

• The therapeutic use of intravenous immunoglobulin is limited to certain imunological disorders such as immune thrombocytopenic purpura and Guillain-Barre syndrome. No conclusive benefit has been demonstrated in patients with sepsis and septic shock.

• The side-effects of intravenous immunoglobulin are immune complex formation, increased immunoglobulin levels, and infection transmission.

• Monoclonal antibodies against lipid A and tumor necrosis factor-a, interleukin 1 receptor antagonist, and platelet activating factor antagonist have not demonstrated a survival benefit in phase III clinical trials of patients with septic shock.

• The administration of murine monoclonal antibodies leads to the production of human anti-mouse antibodies.

• Granulocyte colony-stimulating factor augments neutrophil number and function and reduces infectious complications during myeloablative chemotherapy.

• There are no convincing data for the use of colony-stimulating factors in critically ill patients with pneumonia and septic shock.

Was this article helpful?

0 0
Kicking Fear And Anxiety To The Curb

Kicking Fear And Anxiety To The Curb

Kicking Fear And Anxiety To The Curb Can Have Amazing Benefits For Your Life And Success. Learn About Calming Down And Gain Power By Learning Ways To Become Peaceful And Create Amazing Results.

Get My Free Ebook

Post a comment